Search hospitals > Hawaii > Honolulu

Queen's Cancer Center - Kuakini

Claim this profile
Honolulu, Hawaii 96813
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
222 reported clinical trials
14 medical researchers
Photo of Queen's Cancer Center - Kuakini in HonoluluPhoto of Queen's Cancer Center - Kuakini in Honolulu

Summary

Queen's Cancer Center - Kuakini is a medical facility located in Honolulu, Hawaii. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Queen's Cancer Center - Kuakini is involved with conducting 222 clinical trials across 340 conditions. There are 14 research doctors associated with this hospital, such as Jeffrey L. Berenberg, Michael Carney, MD, Jared D. Acoba, and Jami A. Fukui.

Area of expertise

1Cancer
Global Leader
Queen's Cancer Center - Kuakini has run 77 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Queen's Cancer Center - Kuakini has run 56 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
ER positive
HER2 negative

Top PIs

Clinical Trials running at Queen's Cancer Center - Kuakini

Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Diffuse Large B-Cell Lymphoma
Ovarian Cancer
Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Bladder Cancer
Fallopian Tube Cancer
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Queen's Cancer Center - Kuakini?
Queen's Cancer Center - Kuakini is a medical facility located in Honolulu, Hawaii. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Queen's Cancer Center - Kuakini is involved with conducting 222 clinical trials across 340 conditions. There are 14 research doctors associated with this hospital, such as Jeffrey L. Berenberg, Michael Carney, MD, Jared D. Acoba, and Jami A. Fukui.